Avacta Group plc
("Avacta" or the "Group" or the "Company")
Result of AGM
LONDON and PHILADELPHIA - July, 2 2025 - Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted oncology drugs, today announces that at the Annual General Meeting (AGM) held this morning, all resolutions were duly passed by shareholders (with the exception of Resolution 3 which was not put to the meeting).
The results of the voting at the AGM are outlined in the table below and the presentation materials are available on the Company's website here.
|
For |
Against |
Withheld |
|||
|
Resolution |
Votes |
% |
Votes |
% |
Votes |
|
1 |
69,286,714 |
99.84% |
111,935 |
0.16% |
2,231,336 |
|
2 |
52,723,506 |
77.25% |
15,527,142 |
22.75% |
3,379,337 |
|
3 |
See above |
- |
See above |
- |
See above |
|
4 |
70,378,158 |
99.32% |
482,896 |
0.68% |
768,931 |
|
5 |
68,687,888 |
98.79% |
843,416 |
1.21% |
2,098,681 |
|
6 |
68,241,916 |
97.50% |
1,747,126 |
2.50% |
1,640,943 |
|
7 |
70,242,593 |
99.58% |
293,323 |
0.42% |
1,094,069 |
|
8 |
61,988,039 |
90.99% |
6,139,673 |
9.01% |
3,502,273 |
|
9 |
64,805,029 |
98.71% |
850,095 |
1.29% |
5,974,861 |
|
10 |
65,957,356 |
97.83% |
1,462,237 |
2.17% |
4,210,392 |
|
11 |
64,414,344 |
96.66% |
2,229,203 |
3.34% |
4,986,438 |
|
12 |
64,418,047 |
96.71% |
2,189,948 |
3.29% |
5,021,990 |
|
13 |
67,217,793 |
99.14% |
580,188 |
0.86% |
3,832,004 |
Although all the resolutions were passed, the Board of Avacta notes that more than 20% of votes were cast against Resolution 2. The Board will continue to engage with shareholders in the periods ahead and remains committed to open and constructive dialogue in order to understand shareholders' views. To this end, shareholders who voted against resolution 2 can email any views to avacta@icrhealthcare.com.
-Ends -
For further information from Avacta Group plc, please contact:
|
Avacta Group plc Michael Vinegrad, Group Communications Director |
|
|
Peel Hunt (Nomad and Joint Broker) James Steel / Chris Golden |
|
|
Panmure Liberum (Joint Broker) Emma Earl / Will Goode / Mark Rogers Zeus (Joint Broker) James Hornigold / George Duxberry Dominic King ICR Healthcare Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert |
|
|
Investor Contact Renee Leck THRUST Strategic Communications |
|
|
Media Contact Carly Scaduto Carly Scaduto Consulting |
About Avacta - https://avacta.com/
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.